P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL

Gelijkaardige items

• Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology
  door: Bouke P.C. Hazenberg, et al.
  Gepubliceerd in: (2015-05-01)
• Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
  door: Christof Scheid, et al.
  Gepubliceerd in: (2014-01-01)
• Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
  door: Henk M. Lokhorst, et al.
  Gepubliceerd in: (2008-01-01)
• Rituximab maintenance therapy: a step forward in follicular lymphoma
  door: Marinus H.J. van Oers
  Gepubliceerd in: (2007-06-01)
• Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
  door: Monique C. Minnema, et al.
  Gepubliceerd in: (2019-11-01)